Deliver 500,000 additional doses of bamlanivimab to the U.S. government
The company cancelled or abandoned the commitment
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Jan 2021
- Due
- 31 Mar 2021
- Withdrawn
- 27 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“an agreement earlier this week to deliver 500,000 additional doses no later than March 31, 2021.”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2021.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Delivery
- Indicative materiality
- Medium rules
- Action
- Deliver
- Deliverable
- 500,000 doses of bamlanivimab
- Target
- 500,000 doses
- Where
- U.S.
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LLY-004042 · Corrections policy